[go: up one dir, main page]

FI974323A0 - Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten - Google Patents

Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten

Info

Publication number
FI974323A0
FI974323A0 FI974323A FI974323A FI974323A0 FI 974323 A0 FI974323 A0 FI 974323A0 FI 974323 A FI974323 A FI 974323A FI 974323 A FI974323 A FI 974323A FI 974323 A0 FI974323 A0 FI 974323A0
Authority
FI
Finland
Prior art keywords
parkinsonism
treatment
selective nmda
nmda antagonists
combinations containing
Prior art date
Application number
FI974323A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI974323L (fi
FI974323A7 (fi
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI974323L publication Critical patent/FI974323L/fi
Publication of FI974323A7 publication Critical patent/FI974323A7/fi
Publication of FI974323A0 publication Critical patent/FI974323A0/fi

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Multimedia (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
FI974323A 1995-05-26 1995-05-26 Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten FI974323A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (fr) 1995-05-26 1995-05-26 Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (3)

Publication Number Publication Date
FI974323L FI974323L (fi) 1997-11-25
FI974323A7 FI974323A7 (fi) 1997-11-25
FI974323A0 true FI974323A0 (fi) 1997-11-25

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974323A FI974323A0 (fi) 1995-05-26 1995-05-26 Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten

Country Status (26)

Country Link
US (1) US6258827B1 (fr)
EP (1) EP0828513B1 (fr)
JP (1) JPH11505828A (fr)
CN (1) CN1159325A (fr)
AT (1) ATE258067T1 (fr)
AU (1) AU696258B2 (fr)
BR (1) BR9602485A (fr)
CA (1) CA2219911C (fr)
CO (1) CO4700422A1 (fr)
CZ (1) CZ283979B6 (fr)
DE (1) DE69532482T2 (fr)
DK (1) DK0828513T3 (fr)
ES (1) ES2211904T3 (fr)
FI (1) FI974323A0 (fr)
HU (1) HUP9601419A3 (fr)
IL (1) IL118328A (fr)
MX (1) MX9709112A (fr)
NO (1) NO962130L (fr)
NZ (1) NZ286656A (fr)
PL (1) PL314413A1 (fr)
PT (1) PT828513E (fr)
RU (1) RU2176145C2 (fr)
SG (1) SG45479A1 (fr)
TR (1) TR199600436A2 (fr)
TW (1) TW470740B (fr)
WO (1) WO1996037226A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
WO1999021539A1 (fr) * 1997-10-24 1999-05-06 Warner-Lambert Company Methode de traitement de dyskinesies liees a une maladie ou provoquees par l'absorption de medicaments
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
EP1186303A3 (fr) * 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
BR0207526A (pt) 2001-02-23 2004-03-09 Merck & Co Inc Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
WO2002069974A1 (fr) * 2001-03-05 2002-09-12 Andrew Holman Administration d'agents restaurateurs de sommeil
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
HK1080408B (en) * 2002-10-08 2008-08-08 Allergan, Inc. Use of brimonidine in the treatment of dementia and parkinsons disease
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2005023197A2 (fr) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methodes et compositions permettant de prevenir et de traiter les troubles genito-urinaires, en particulier, l'accouchement premature et les leiomyomes
EP1588704A1 (fr) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2281695C1 (ru) * 2004-12-24 2006-08-20 Дмитрий Владимирович Похабов Способ лечения болезни паркинсона
US7713990B2 (en) * 2005-01-13 2010-05-11 Neurosearch A/S 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors
EP1874282B1 (fr) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Procedes et compositions pour le traitement des pathologies associees au systeme nerveux central
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (fr) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
EP2170334B1 (fr) 2007-06-29 2021-03-17 Emory University Antagonistes des récepteurs nmda pour la neuroprotection
RU2393860C2 (ru) * 2008-05-30 2010-07-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Использование тизанидина в качестве корректора лекарственного паркинсонизма
WO2009147681A1 (fr) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Compositions pharmaceutiques pour le traitement de la maladie de parkinson
RU2386458C1 (ru) * 2008-09-04 2010-04-20 Государственное Учреждение Научный Центр Неврологии Российской Академии Медицинских Наук Способ лечения болезни паркинсона
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US9387212B2 (en) * 2012-04-20 2016-07-12 Ucb Biopharma Sprl Methods for treating Parkinson's disease
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5356905A (en) 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
DE9290042U1 (de) 1991-04-18 1993-12-16 Pfizer Inc., New York, N.Y. Pro-Arzneimittelester von phenolischen 2-Piperidino-1-alkanolen
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
RU2000114C1 (ru) * 1991-07-18 1993-09-07 Васильев В.Н. Способ Васильева В.Н. лечени заболеваний, св занных с недостаточностью дофаминового обмена

Also Published As

Publication number Publication date
US6258827B1 (en) 2001-07-10
EP0828513B1 (fr) 2004-01-21
WO1996037226A2 (fr) 1996-11-28
MX9709112A (es) 1998-02-28
NO962130D0 (no) 1996-05-24
ES2211904T3 (es) 2004-07-16
DK0828513T3 (da) 2004-04-13
DE69532482D1 (de) 2004-02-26
PT828513E (pt) 2004-05-31
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
HUP9601419A2 (en) 1997-09-29
EP0828513A2 (fr) 1998-03-18
CA2219911A1 (fr) 1996-11-28
CZ152496A3 (cs) 1998-04-15
NZ286656A (en) 2001-03-30
CZ283979B6 (cs) 1998-07-15
FI974323L (fi) 1997-11-25
AU5451996A (en) 1996-12-05
WO1996037226A3 (fr) 1996-12-27
JPH11505828A (ja) 1999-05-25
BR9602485A (pt) 1998-04-22
ATE258067T1 (de) 2004-02-15
NO962130L (no) 1996-11-27
PL314413A1 (en) 1996-12-09
TR199600436A2 (tr) 1996-12-21
FI974323A7 (fi) 1997-11-25
CN1159325A (zh) 1997-09-17
TW470740B (en) 2002-01-01
AU696258B2 (en) 1998-09-03
IL118328A (en) 2001-06-14
IL118328A0 (en) 1996-09-12
CA2219911C (fr) 2004-07-27
CO4700422A1 (es) 1998-12-29
HU9601419D0 (en) 1996-07-29
DE69532482T2 (de) 2004-11-25
HUP9601419A3 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
FI974323A0 (fi) Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
EP0900568A3 (fr) Antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
IL157413A0 (en) Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
MY118944A (en) Synergistic treatment for parkinsonism
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
Sahadevan et al. A comparative experimental study of the anticonvulsant effect of three calcium channel blockers in albino mice
EP0900567A3 (fr) Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
Gowri Thilagam et al. Anti convulsant property of Melatonin in Electro and Chemo induced Convulsions in Rats.
BR9909791A (pt) Tratamento de distúrbios de ansiedade de modo geral com a partoxetina
NO951865L (no) Quinuclidin-derivat som substans-P antagonist

Legal Events

Date Code Title Description
MA Patent expired